Abstract:The prospective cohort study by Ibrahim Abubakar and colleagues reports the predictive values of the tuberculin skin test (TST) and two interferon-γ release assays (IGRAs) for the development of active tuberculosis.1Abubakar I Drobniewski F Southern J et al.Prognostic value of interferon-gamma release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study.Lancet Infect Dis. 2018; 18: 1077-1087Summary Full Text Full Text PDF PubMed Scopus (96) Google Scholar The detection of individuals with latent infection who are likely to progress to active disease presents major challenges. 1·7 billion individuals were estimated to be latently infected with tuberculosis globally and about 10% of those will develop active disease.2Houben RM Dodd PJ The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling.PLoS Med. 2016; 13: e1002152Crossref PubMed Scopus (933) Google Scholar However, there are no available tests that precisely identify which individuals will develop disease. Consequently, preventive treatment is given to at-risk groups that inevitably include individuals who would not have progressed to disease.3Barry CR Boshoff HI Dartois V et al.The spectrum of latent tuberculosis: rethinking the biology and intervention strategies.Nat Rev Microbiol. 2009; 7: 845-855Crossref PubMed Scopus (988) Google Scholar Additionally, although anti-tuberculosis treatment with 4 months of rifampicin or 9 months of isoniazid can prevent development of active disease from latent infection,4Menzies D Adjobimey M Ruslami R et al.Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults.N Engl J Med. 2018; 379: 440-453Crossref PubMed Scopus (198) Google Scholar poor adherence, toxic effects, and low cost–effectiveness ratio hinder application of these therapies in high-burden low-income countries. Accordingly, a low-cost method of predictive screening for latent tuberculosis is urgently needed. Notably, this study showed that TST-15, a TST with a threshold greater than 5 mm in individuals naive to BCG or 15 mm in those vaccinated with BCG, provided a low-cost screening method to predict the development of disease that was almost as accurate as more expensive IGRAs, even after BCG vaccination. Abubakar and colleagues did not directly consider the possible effect of non-tuberculosis mycobacteria (NTM) infections, which are also a serious problem in countries with a high burden of tuberculosis. The cross-reactivity might increase the false positivity of TST. By contrast, the immune stimulators used in IGRAs are absent from BCG and NTM strains, and Abubakar and colleagues' study showed that the predictive value of IGRAs was slightly higher than that of TST-15. However, the higher cost of IGRAs hinders their application in lower-income countries. Previously, we reported on the use of recombinant fusion protein ESAT-6–CFP10 for skin tests of tuberculosis infection and showed that it had an accuracy similar to that of IGRAs in diagnosing patients with tuberculosis in clinical trials.5Li F Xu M Qin C et al.Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial.Clin Microbiol Infect. 2016; 22: 889.e9-889.e16Summary Full Text Full Text PDF Scopus (21) Google Scholar, 6Li F Xu M Zhou L et al.Safety of recombinant fusion protein ESAT6-CFP10 as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, single-center phase I clinical trial.Clin Vaccine Immunol. 2016; 23: 767-773Crossref PubMed Scopus (13) Google Scholar In a phase 2a trial (NCT02329730),5Li F Xu M Qin C et al.Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial.Clin Microbiol Infect. 2016; 22: 889.e9-889.e16Summary Full Text Full Text PDF Scopus (21) Google Scholar we have further shown that ESAT-6-CFP10 use has similar accuracy to that of T-SPOT.TB in diagnosing tuberculosis infection in healthy volunteers and in patients with active tuberculosis infection (table). Nevertheless, TST-5 (a TST with a threshold of 5 mm) showed significantly higher positivity in healthy volunteers, which indicates high cross-reactivity from BCG vaccination (table). The low cost of this approach will facilitate its application in low-income countries.TableUse of recombinant fusion protein ESAT-6–CFP10 for skin tests of tuberculosis infection in a phase 2a clinical trialHealthy volunteersPatients with active tuberculosisCasesPositive casesPositivity (%)CasesPositive casesPositivity (%)TST-5*Purified protein derivative skin test with a threshold of 5 mm with a 5 IU inoculation.563257·1%534584·9%ESAT-6–CFP10†ESAT-6–CFP10 skin test with a threshold of 5 mm with a 10 μg antigen inoculation.5647·1%534381·1%T-SPOT.TB5658·9%534584·9%TST=tuberculosis skin test.* Purified protein derivative skin test with a threshold of 5 mm with a 5 IU inoculation.† ESAT-6–CFP10 skin test with a threshold of 5 mm with a 10 μg antigen inoculation. Open table in a new tab TST=tuberculosis skin test. Abubakar and colleagues included migrants, defined as people who had arrived within 5 years from high-burden countries, in the high-risk group in their study. This grouping criterion is questionable because many migrants might not have contacted patients with active tuberculosis. In the online appendix, the authors showed that the TST positivity was lower in migrants than in contacts (20·8% vs 33·7% in TST-15). Additionally, the percentage of disease progression in migrants was lower than in contacts. Therefore, the inclusion of migrants might have resulted in under-indication of the predictive values, and these values might actually be very different in high-risk groups with different criteria. It is regrettable that the opportunity to do sequential tests of immune responses during follow-up was missed. Dynamic changes in immune markers might reveal better indicators for disease emerging from latent infection. It has been shown that early CD4 T-cell activation was correlated with tuberculosis disease risk after infection,7Fletcher HA Snowden MA Landry B et al.T-cell activation is an immune correlate of risk in BCG vaccinated infants.Nat Commun. 2016; 7: 11290Crossref PubMed Scopus (183) Google Scholar and we found that the expression of KLRG1, a marker of terminally differentiated T cells, was increased in patients with tuberculosis.8Hu Z Zhao HM Li CL et al.The Role of KLRG1 in human CD4+ T-cell immunity against tuberculosis.J Infect Dis. 2018; 217: 1491-1503Crossref PubMed Scopus (22) Google Scholar Therefore, further studies combining assays of defined immune markers with TST, IGRAs, or ESAT-6–CFP10 skin test might reveal a better method to predict progression to disease. We declare no competing interests. This work was supported by Grants from Chinese National Mega Science and Technology Program on Infectious Diseases (2018ZX10302301, 2018ZX10731301), National Science Foundation of China (31771004, 81873884, 81501365, 81770011), and Shanghai Science and Technology Commission (17ZR1423900). Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort studyIGRA-based or BCG-stratified TST strategies appear most suited to screening for potential disease progression among high-risk groups. Further work will be needed to assess country-specific cost-effectiveness of each screening test, and in the absence of highly specific diagnostic tests, cheap non-toxic treatments need to be developed that could be given to larger groups of people at potential risk. Full-Text PDF Open Access

Estimated rates of progression to tuberculosis disease for persons infected with Mycobacterium tuberculosis in the United States

Updates on the Risk Factors for Latent Tuberculosis Reactivation and Their Managements.

Tuberculosis Among Foreign-Born Persons Diagnosed ≥10 Years After Arrival in the United States, 2010–2015

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection

Prevalence Trends of Latent Tuberculosis Infection at the Global, Regional, and Country Levels from 1990–2019

Overlooked, dismissed, and downplayed: reversion of Mycobacterium tuberculosis immunoreactivity

Latent Tuberculosis Infection Testing Practices in a Large US Integrated Healthcare System

Incidence and Risk Factors of Active Tuberculosis Among Hospitalized Patients with Latent Tuberculosis Infection in China: A Cohort Study

Timing and Predictors of Tuberculosis Incidence among Contacts

Latent Mycobacterium tuberculosis infection.

Age-specific prevalence of TB infection among household contacts of pulmonary TB: Is it time for TB preventive therapy?

Latent tuberculosis infection and incident cardiovascular and non-cardiovascular death

Recurrent Pulmonary Tuberculosis in China, 2005 to 2021

Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis

The Predictive Values of the Tuberculin Skin Test and Interferon-Γ Release Assays for Active Tuberculosis Development.

Risk of progression to active tuberculosis for indeterminate interferon-gamma release assay in immunocompromised individuals: A systematic review and meta-analysis

Mycobacterium tuberculosis is less likely to acquire pathogenic mutations during latent infection than during active disease

Smoking Exposure and the Risk of Latent Tuberculosis Infection: Results from NHANES 2011–2012

Association between Smoking and Latent Tuberculosis in the U.S. Population: An Analysis of the National Health and Nutrition Examination Survey

Risk factors for and timing of presumptive recurrent TB

Patients at high risk of tuberculosis recurrence